 |
International Journal for Research Trends and Innovation
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-3315 | Impact factor: 8.14 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.14 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
|
Issue: December 2025
Volume 10 | Issue 12
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.14
Issue per Year : 12
Volume Published : 10
Issue Published : 115
Article Submitted : 19446
Article Published : 8041
Total Authors : 21252
Total Reviewer : 769
Total Countries : 144
Indexing Partner
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Protac technology of degrading unhealthy proteins - A futuristic approach therapy for alzheimer`s and cancer disorders |
| Authors Name: | Sirisha Kodali , Monika Moorthi , Manimekalai Pichaivel |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJRTI_188490
|
| Published Paper Id: | IJRTI2311056 |
| Published In: | Volume 8 Issue 11, November-2023 |
| DOI: | https://doi.org/10.5281/zenodo.10675466 |
| Abstract: | In recent decades, a promising therapeutic strategy called Proteolysis-Targeting Chimera (PROTAC) therapy has emerged as a potential breakthrough in the field of drug development. PROTACs are bifunctional molecules designed to degrade disease-associated proteins by harnessing the cellular machinery responsible for protein turnover. Alzheimer's disease and cancer are two devastating and prevalent diseases have limited treatment options. In Alzheimer's disease, the accumulation of misfolded proteins, such as amyloid-beta (Aβ) and tau, contributes to the neurodegenerative processes. Current therapeutic strategies for Alzheimer's disease focus on reducing the levels of these protein aggregates. Preclinical studies utilizing PROTACs against Aβ and tau have demonstrated promising results in promoting protein clearance and improving cognitive function in animal models, suggesting their therapeutic potential for Alzheimer's disease. In the realm of cancer treatment, aberrant protein expression or dysregulated signalling pathways often drive tumorigenesis. Traditional cancer therapies typically target these proteins directly. However, acquired resistance and off-target effects limit the efficacy of such treatments. PROTAC therapy provides a new avenue by inducing the degradation of disease-driving proteins, offering the advantage of targeting proteins that were previously considered "undruggable." Several PROTACs have shown efficacy in degrading oncogenic proteins, leading to tumor regression and improved outcomes in preclinical models and early-phase clinical trials. Despite the enormous potential of PROTAC therapy, several challenges remain. Optimization of PROTAC design, such as enhancing target selectivity and stability, is crucial for its successful clinical translation. Nevertheless, PROTAC therapy represents a promising and innovative strategy for the treatment of both Alzheimer's disease and cancer treatment. This review aims to provide an overview of the application of PROTAC therapy in both Alzheimer's disease and cancer, highlighting its potential as a transformative treatment approach. |
| Keywords: | PROTAC therapy; Alzheimer's disease; Cancer; Protein degradation; Neurodegeneration; Tumorigenesis. |
| Cite Article: | "Protac technology of degrading unhealthy proteins - A futuristic approach therapy for alzheimer`s and cancer disorders", International Journal of Science & Engineering Development Research (www.ijrti.org), ISSN:2455-2631, Vol.8, Issue 11, page no.398 - 407, November-2023, Available :http://www.ijrti.org/papers/IJRTI2311056.pdf |
| Downloads: | 000205130 |
| ISSN: |
2456-3315 | IMPACT FACTOR: 8.14 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.14 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID: IJRTI2311056
Registration ID:188490
Published In: Volume 8 Issue 11, November-2023
DOI (Digital Object Identifier): https://doi.org/10.5281/zenodo.10675466
Page No: 398 - 407 Country: Namakkal, Tamilnadu, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijrti.org/viewpaperforall?paper=IJRTI2311056 Published Paper PDF: https://www.ijrti.org/papers/IJRTI2311056 |
| Share Article: | |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijrti.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-3315
Impact Factor: 8.14 and ISSN APPROVED,
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
| Providing A digital object identifier by DOI.ONE How to Get DOI? |
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Join RMS/Earn 300
WhatsApp
Click Here
Click Here
Indexing Partner |
|||
| Copyright © 2025 - All Rights Reserved - IJRTI | |||